Markets / events / KXFDAAPPROVE / KXFDAAPPROVE-V940 Will the FDA approve intismeran autogene (V940/mRNA-4157)? intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma Science and Technology independent outcomes
Open on kalshi.com 24h volume
0
contracts, all markets
Open interest
351
contracts, all markets
Series
Will the FDA approve drug?
Markets in this event Sorted by 24h volume.
Show JSON (markets omitted) event 12 category Science and Technology
collateral_return_type
Before Jul 1, 2027
KXFDAAPPROVE-V940-27JUL01
event_ticker KXFDAAPPROVE-V940
last_updated_ts 0001-01-01T00:00:00Z
product_metadata 2 competition Moderna and Merck
competition_scope Approval
series_ticker KXFDAAPPROVE
settlement_sources 1 [0] 2 name Food and Drug Administration
url https://www.fda.gov/news-events/fda-newsroom/press-announcements
sub_title intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma
title Will the FDA approve intismeran autogene (V940/mRNA-4157)?